Oncology

Latest News

The findings suggest that inhibition of midkine might be a meaningful tool to improve treatment outcomes in SCLC. | Image credit: Pixel-Shot - stock.adobe.com

July 24th 2025

New data show midkine expression is heightened in small cell lung cancer, suggesting the growth factor may be an important therapeutic target.

The FDA has issued a complete response letter for RP1 plus nivolumab for advanced melanoma after a PD-1 inhibitor–containing regimen. | Image credit: ra2studio - stock.adobe.com

RP1 Plus Nivolumab Receives CRL for Advanced Melanoma

By Chris Ryan

July 24th 2025

David Nguyen, MD | Image Credit: Tufts Medicine

It Take a Village in Cancer Care: A Q&A With David Nguyen, MD

By Maggie L. Shaw
David Nguyen, MD

July 23rd 2025

In Data Race, Flatiron Health Touts Tripling of Global Oncology Research Network

By Mary Caffrey

July 23rd 2025

Emerging therapies, including immune checkpoint inhibitors and antibody-drug conjugates, could significantly impact SCLC treatment, authors of a recent review concluded. | Image credit: Vitalii Vodolazskyi - stock.adobe.com

Is a New Era of SCLC, LCNEC Treatments on the Horizon?

By AJMC Contributor

July 23rd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

View All

July 25th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

July 25th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

February 6th 2016

Lipegfilgrastim a Possible Alternative for Managing Chemotherapy-Induced Neutropenia

Jessica Men

The novel molecule lipegfilgrastim has been shown to be relatively equivalent to pegfilgrastim in the management of chemotherapy-induced neutropenia among patients with breast cancer.

February 5th 2016

AJMC Staff

Scientists at the FDA have provided their recommendation to be submitted to an independent medical advisory panel that will decide the fate of Remsima.

February 5th 2016

Cancer Treatment Financially Devastating in Young Adult Survivors, Says Samfund Study

Surabhi Dangi-Garimella, PhD

The paper in Cancer Medicine finds that cancer has a devastating and age-specific impact on the finances of young adult survivors.

February 5th 2016

Where Does Immuno-Oncology Fit in a Value-Based Care Delivery Model?

Bruce Feinberg, DO

Advances made in the field of immuno-oncology (I-O) in 2015 have greatly expanded our understanding of I-O and added more complexity to its value assessment.

February 5th 2016

The Fight of Our Lives: Confronting the Unmet Need in Lung Cancer

Bonnie J. Addario

Supporting, funding, and protecting the research and development of new medicines and new treatments is more critical, now than ever, to provide better treatments and better outcomes to all cancer patients.

February 4th 2016

High Risks, High Costs Associated With Febrile Neutropenia in Metastatic Cancer

Jackie Syrop

Data from 2 large studies of patients with metastatic disease who underwent myelosuppressive chemotherapy found that febrile neutropenia occurred in approximately 13% to 21% of patients. Associated costs of febrile neutropenia were found to range from $16,000 to $19,000 per episode for most hospitalized patients.

February 4th 2016

ASCO Highlights the Year in Oncology Advances

Laura Joszt, MA

The annual Clinical Cancer Advances report from the American Society of Clinical Oncology highlights the accomplishments made in the last year in the fight against cancer.

February 4th 2016

On World Cancer Day, Stories of Courage and Support

Surabhi Dangi-Garimella, PhD

On World Cancer Day, The American Journal of Managed Care would like to acknowledge the determination of cancer survivors and the support provided by various organizations to patients and their families.

February 4th 2016

Immuno-Oncology 2016 and Beyond: The Opportunities, Challenges, and Risks

Michael V. Seiden, MD, PhD

The translation of immuno-oncology agents from the research to the practice arena may provide significant clinical benefit to patients with difficult-to-treat malignancies. The further development and marketing of these agents could escalate the discussion on care equity in a time of constrained resources.

February 3rd 2016

Fight With or Adapt to Rising Drug Prices? Economists Debate at the AcademyHealth Conference

Surabhi Dangi-Garimella, PhD

Rising drug prices, the effect on the healthcare system, consumer push-back, and possible solutions were debated by the expert panel.

February 3rd 2016

Molecular Testing Patterns in Metastatic Non—Small Cell Lung Cancer

Elizabeth MacLean, PharmD Anthony Louder, PhD, RPh Kim Saverno, PhD, RPh Gregory Smith, BA Jack Mardekian, PhD Cari Bruins, PharmD Melea Ward, PharmD, PhD Robert Sweetman, MD Margaret Pasquale, PhD

Assessment of the timing of histologic and molecular testing indicates that testing occurred prior to treatment initiation for most patients with metastatic nonâ€”small cell lung cancer.

February 2nd 2016

Rationing Care in Times of Drug Shortages

Surabhi Dangi-Garimella, PhD

Pediatric oncologists from across the country covened a task force to develop an ethical framework that guides decisions on allocation based on curability, prognosis, and the incremental importance of a drug to a patient’s outcome

February 2nd 2016

Comparing End-of-Life Care for Cancer Patients in 7 Developed Countries

Priyam Vora

Among 7 developed countries, the United States has the lowest proportion of deaths that occur in the hospital and the lowest number of days spent in the hospital during the last 6 months of life.

February 1st 2016

How Successful Will Gleevec's Generic Competitor Be?

Surabhi Dangi-Garimella, PhD

The generic manufacturer may try to maximize profits during the initial exclusivity period, says an expert from a leading health plan.

February 1st 2016

Will New Evidence for Proton Radiotherapy Swing Payers?

Surabhi Dangi-Garimella, PhD

With increasing evidence of comparable efficacy and reduced toxicity of proton beam therapy, payers may have to reevaluate coverage policies.

February 1st 2016

What We're Reading: Cancer Moonshot Creates Hard Feelings With Some Researchers

AJMC Staff

What we're reading, February 1, 2016: some medical researchers disagree with sharing raw data used in their research; the medical community is torn on whether or not the annual checkup is worthwhile; and Donald Trump vows to extend healthcare coverage to the lower class.

January 31st 2016

Early Palliative Care for Cancer Patients With More Comorbidities Reduces Cost

Priyam Vora

Providing cancer patients with multiple life-threatening conditions with earlier palliative care consultation can be helpful in bringing down healthcare spending in enormous proportions, according to a new study published in Health Affairs.

January 30th 2016

This Week in Managed Care: January 30, 2016

Top managed care news of the week includes new recommendation to screen all adults for depression, new issue of The American Journal of Managed Care places attention on mental health care, and Donald Trump calls for Medicare to negotiate drug prices.

January 30th 2016

Tbo-Filgrastim Can Replace Filgrastim During ASCT in Myeloma and Lymphoma

AJMC Staff

A study presented at the annual meeting of the American Society of Hematology concluded that tbo-filgrastim is similar to filgrastim for ASCT mobilization in patients with MM or NHL.

January 29th 2016

Study Identifies Disparity in Survival of AYA Hodgkin Lymphoma

Surabhi Dangi-Garimella, PhD

Mortality in adolescent and young adult Hodgkin lymphoma patients is significantly affected by ethnic and socioeconomic factors, as well as insurance status, according to a new study published in Cancer Epidemiology, Biomarkers & Prevention.

January 29th 2016

Do Hematologists Believe APMs Afford Fair Value? An Open Discussion at ASH

Surabhi Dangi-Garimella, PhD

At the annual meeting of the American Society of Hematology, physicians gathered to discuss the impact of alternate payment models on clinical practice.

January 29th 2016

Does Geographic Location Influence Healthcare Utilization in Children With Lymphoma?

Surabhi Dangi-Garimella, PhD

A study presented at the 57th meeting of the American Society of Hematology finds that distance from the site of care could could adversely affect outcomes in children with acute lymphoblastic leukemia and acute myeloid leukemia.

January 29th 2016

Healthcare Utilization in Children With Sickle Cell Disease

Surabhi Dangi-Garimella, PhD

At the annual meeting of the American Society of Hematology, researchers from the Aflac Cancer and Blood Disorders Center presented analysis evaluating the factors that influence health outcomes in children with sickle cell disease.

January 29th 2016

5 Things to Know About Clinical Pathways

Surabhi Dangi-Garimella, PhD

Learn where clinical care pathways stand today and what the future holds with respect to developing and implementing them.

January 28th 2016

FDA Advocates for Diversity in Clinical Trials

Surabhi Dangi-Garimella, PhD

The FDA has created the Drug Trial Snapshot, which provides details on the demographic profiles of participants in clinical trials of approved drugs.

January 28th 2016

Three Proposals That Would Kill the 340B Program

Robert Chapman, MD

The 3 prescriptions for reforming the 340B Drug Discount Program proposed by authors in the December issue of Evidence-Based Oncology would limit safety net hospitals' abilities to treat vulnerable patients.

January 28th 2016

Nivolumab Improved OS in SCCHN; CheckMate-141 Stopped Early

Surabhi Dangi-Garimella, PhD

A review by an independent Data Monitoring Committee found that nivolumab improved overall survival in patients with squamous cell carcinoma of the head and neck, compared with the control arm.

January 27th 2016

Study Shows Academic Hospitals Better at Caring for ALL Patients

Surabhi Dangi-Garimella, PhD

A study presented during a health outcomes session at the American Society of Hematology meeting evaluated the difference in overall survival in patients with acute lymphoblastic leukemia treated in academic versus nonacademic hospitals.

January 27th 2016

Insurance Status Determines OS in Patients With CML

Surabhi Dangi-Garimella, PhD

Results presented at the annual meeting of the American Society of Hematology found that many patients diagnosed with chronic myeloid leukemia may not have access to or receive appropriate care, in part due to their insurance coverage.

January 27th 2016

Importance of Patient-Reported Outcomes and Quality-of-Life Measures in Myeloid Disease

Surabhi Dangi-Garimella, PhD

Results from a patient-reported outcomes measure of symptoms and symptom burden, experienced by patients with acute myeloid leukemia and myelodysplastic syndrome, were presented at the 57th annual meeting of the American Society of Hematology.

...

111 112 113 114 115 116 117 118 119

...

187 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions